157 related articles for article (PubMed ID: 22614669)
1. Blockade of the brain histamine H3 receptor by JNJ-39220675: preclinical PET studies with [¹¹C]GSK189254 in anesthetized baboon.
Logan J; Carruthers NI; Letavic MA; Sands S; Jiang X; Shea C; Muench L; Xu Y; Carter P; King P; Fowler JS
Psychopharmacology (Berl); 2012 Oct; 223(4):447-55. PubMed ID: 22614669
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of 11C-GSK189254 as a novel radioligand for the H3 receptor in humans using PET.
Ashworth S; Rabiner EA; Gunn RN; Plisson C; Wilson AA; Comley RA; Lai RY; Gee AD; Laruelle M; Cunningham VJ
J Nucl Med; 2010 Jul; 51(7):1021-9. PubMed ID: 20554726
[TBL] [Abstract][Full Text] [Related]
3. Novel histamine H3 receptor antagonists GSK189254 and GSK334429 are efficacious in surgically-induced and virally-induced rat models of neuropathic pain.
Medhurst SJ; Collins SD; Billinton A; Bingham S; Dalziel RG; Brass A; Roberts JC; Medhurst AD; Chessell IP
Pain; 2008 Aug; 138(1):61-69. PubMed ID: 18164820
[TBL] [Abstract][Full Text] [Related]
4. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models.
Medhurst AD; Atkins AR; Beresford IJ; Brackenborough K; Briggs MA; Calver AR; Cilia J; Cluderay JE; Crook B; Davis JB; Davis RK; Davis RP; Dawson LA; Foley AG; Gartlon J; Gonzalez MI; Heslop T; Hirst WD; Jennings C; Jones DN; Lacroix LP; Martyn A; Ociepka S; Ray A; Regan CM; Roberts JC; Schogger J; Southam E; Stean TO; Trail BK; Upton N; Wadsworth G; Wald JA; White T; Witherington J; Woolley ML; Worby A; Wilson DM
J Pharmacol Exp Ther; 2007 Jun; 321(3):1032-45. PubMed ID: 17327487
[TBL] [Abstract][Full Text] [Related]
5. 11C-GSK189254: a selective radioligand for in vivo central nervous system imaging of histamine H3 receptors by PET.
Plisson C; Gunn RN; Cunningham VJ; Bender D; Salinas CA; Medhurst AD; Roberts JC; Laruelle M; Gee AD
J Nucl Med; 2009 Dec; 50(12):2064-72. PubMed ID: 19910432
[TBL] [Abstract][Full Text] [Related]
6. AZD5213: a novel histamine H3 receptor antagonist permitting high daytime and low nocturnal H3 receptor occupancy, a PET study in human subjects.
Jucaite A; Takano A; Boström E; Jostell KG; Stenkrona P; Halldin C; Segerdahl M; Nyberg S
Int J Neuropsychopharmacol; 2013 Jul; 16(6):1231-9. PubMed ID: 23217964
[TBL] [Abstract][Full Text] [Related]
7. Regional differential effects of the novel histamine H3 receptor antagonist 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide hydrochloride (GSK189254) on histamine release in the central nervous system of freely moving rats.
Giannoni P; Medhurst AD; Passani MB; Giovannini MG; Ballini C; Corte LD; Blandina P
J Pharmacol Exp Ther; 2010 Jan; 332(1):164-72. PubMed ID: 19815811
[TBL] [Abstract][Full Text] [Related]
8. In vivo receptor occupancy assay of histamine H₃ receptor antagonist in rats using non-radiolabeled tracer.
Nirogi R; Kandikere V; Bhyrapuneni G; Muddana N; Saralaya R; Ponnamaneni RK; Manoharan AK
J Pharmacol Toxicol Methods; 2012; 65(3):115-21. PubMed ID: 22487318
[TBL] [Abstract][Full Text] [Related]
9. Unexpectedly high affinity of a novel histamine H(3) receptor antagonist, GSK239512, in vivo in human brain, determined using PET.
Ashworth S; Berges A; Rabiner EA; Wilson AA; Comley RA; Lai RY; Boardley R; Searle G; Gunn RN; Laruelle M; Cunningham VJ
Br J Pharmacol; 2014 Mar; 171(5):1241-9. PubMed ID: 24670146
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of acute and repeat dosing with the H3 antagonist GSK189254 on the sleep-wake cycle and narcoleptic episodes in Ox-/- mice.
Guo RX; Anaclet C; Roberts JC; Parmentier R; Zhang M; Guidon G; Buda C; Sastre JP; Feng JQ; Franco P; Brown SH; Upton N; Medhurst AD; Lin JS
Br J Pharmacol; 2009 May; 157(1):104-17. PubMed ID: 19413575
[TBL] [Abstract][Full Text] [Related]
11. Antinociceptive effects of histamine H3 receptor antagonist in the preclinical models of pain in rats and the involvement of central noradrenergic systems.
Hsieh GC; Honore P; Pai M; Wensink EJ; Chandran P; Salyers AK; Wetter JM; Zhao C; Liu H; Decker MW; Esbenshade TA; Cowart MD; Brioni JD
Brain Res; 2010 Oct; 1354():74-84. PubMed ID: 20682302
[TBL] [Abstract][Full Text] [Related]
12. Kinetic analysis of drug-target interactions with PET for characterization of pharmacological hysteresis.
Salinas C; Weinzimmer D; Searle G; Labaree D; Ropchan J; Huang Y; Rabiner EA; Carson RE; Gunn RN
J Cereb Blood Flow Metab; 2013 May; 33(5):700-7. PubMed ID: 23385202
[TBL] [Abstract][Full Text] [Related]
13. Histamine is required for H₃ receptor-mediated alcohol reward inhibition, but not for alcohol consumption or stimulation.
Vanhanen J; Nuutinen S; Lintunen M; Mäki T; Rämö J; Karlstedt K; Panula P
Br J Pharmacol; 2013 Sep; 170(1):177-87. PubMed ID: 23489295
[TBL] [Abstract][Full Text] [Related]
14. JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats.
Galici R; Rezvani AH; Aluisio L; Lord B; Levin ED; Fraser I; Boggs J; Welty N; Shoblock JR; Motley ST; Letavic MA; Carruthers NI; Dugovic C; Lovenberg TW; Bonaventure P
Psychopharmacology (Berl); 2011 Apr; 214(4):829-41. PubMed ID: 21086115
[TBL] [Abstract][Full Text] [Related]
15. Possible use of a H3R antagonist for the management of nonmotor symptoms in the Q175 mouse model of Huntington's disease.
Whittaker DS; Wang HB; Loh DH; Cachope R; Colwell CS
Pharmacol Res Perspect; 2017 Oct; 5(5):. PubMed ID: 28971617
[TBL] [Abstract][Full Text] [Related]
16. Determination of receptor occupancy in the presence of mass dose: [
Gallezot JD; Planeta B; Nabulsi N; Palumbo D; Li X; Liu J; Rowinski C; Chidsey K; Labaree D; Ropchan J; Lin SF; Sawant-Basak A; McCarthy TJ; Schmidt AW; Huang Y; Carson RE
J Cereb Blood Flow Metab; 2017 Mar; 37(3):1095-1107. PubMed ID: 27207170
[TBL] [Abstract][Full Text] [Related]
17. Antagonism of supraspinal histamine H3 receptors modulates spinal neuronal activity in neuropathic rats.
McGaraughty S; Chu KL; Cowart MD; Brioni JD
J Pharmacol Exp Ther; 2012 Oct; 343(1):13-20. PubMed ID: 22729221
[TBL] [Abstract][Full Text] [Related]
18. H3 receptor antagonism enhances NCAM PSA-mediated plasticity and improves memory consolidation in odor discrimination and delayed match-to-position paradigms.
Foley AG; Prendergast A; Barry C; Scully D; Upton N; Medhurst AD; Regan CM
Neuropsychopharmacology; 2009 Nov; 34(12):2585-600. PubMed ID: 19657331
[TBL] [Abstract][Full Text] [Related]
19. Histamine H3 receptor antagonist JNJ-39220675 modulates locomotor responses but not place conditioning by dopaminergic drugs.
Vanhanen J; Kinnunen M; Nuutinen S; Panula P
Psychopharmacology (Berl); 2015 Mar; 232(6):1143-53. PubMed ID: 25308376
[TBL] [Abstract][Full Text] [Related]
20. Discovery and Preclinical Validation of [(11)C]AZ13153556, a Novel Probe for the Histamine Type 3 Receptor.
Schou M; Varnäs K; Jureus A; Ahlgren C; Malmquist J; Häggkvist J; Tari L; Wesolowski SS; Throner SR; Brown DG; Nilsson M; Johnström P; Finnema SJ; Nakao R; Amini N; Takano A; Farde L
ACS Chem Neurosci; 2016 Feb; 7(2):177-84. PubMed ID: 26529287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
